IC
HEPA

Ikarian Capital’s Hepion Pharmaceuticals HEPA Stock Holding History

Ikarian Capital’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-410
Closed -$235K – 130
2022
Q2 		$235K Sell
410
-172
-30% -$143K 0.04% 114
2022
Q1 		$751K Buy
582
+29
+5% +$32K 0.1% 109
2021
Q4 		$630K Hold
553
– – 0.09% 118
2021
Q3 		$847K Sell
553
-812
-59% -$1.3M 0.06% 162
2021
Q2 		$2.7M Buy
+1,365
New +$2.5M 0.22% 109

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Ikarian Capital's HEPA Position: Q3 2022 in Review

Ikarian Capital sold out of Hepion Pharmaceuticals (HEPA) in Q3 2022, closing a stake of 410 shares — an estimated $235K sold.

Ikarian Capital first reported a position in HEPA in Q2 2021 and held it in 5 quarters. The position peaked at $2.7M in Q2 2021. 25 funds tracked by Wall St. Rank hold HEPA as of Q3 2022.

  • Ikarian Capital reported no remaining Hepion Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 410 Hepion Pharmaceuticals shares in Q3 2022, an estimated $235K.
  • Ikarian Capital first reported a position in Hepion Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Ikarian Capital's Hepion Pharmaceuticals position peaked at $2.7M in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.